title: Quetiapine in patients with borderline personality disorder: an open-label trial.
abstract: BACKGROUND
  Quetiapine was assessed in patients diagnosed with borderline personality disorder (BPD) to examine its potential effect on symptoms and explore a tolerated dosing pattern.
  
  
  METHODS
  An open label case series with objective rating measures was undertaken. The study was of 8 weeks duration.
  
  
  RESULTS
  Sixteen research subjects received quetiapine and completed at least one rating. Nine subjects completed the entire 8 week trial. In the LOCF and completer analyses, significant improvement was noted on GAF, SCL-90, BIS, and SIB. Specifically for the LOCF analysis, GAF increased from 57.7 to 64.6 (p = 0.001), SCL-90 decreased from 120.1 to 78.4 (p = 0.004), BIS improved from 73.4 to 59.9 (p = 0.021), and the SIB started at 267.8 and ended at 202.3 (p < 0.001). The average dose of quetiapine for LOCF analysis was 223.4 mg/d and was 286.1 mg/d for the completers. Common side-effects were similar to those seen in schizophrenic patients--sedation and increased appetite.
  
  
  CONCLUSIONS
  Significant reductions in symptoms assessed by objective rating scales were observed in this pilot study of quetiapine administered to subjects with BPD. The dosing strategy in the study was well tolerated.
authors.affiliation: Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
authors.lastname: Adityanjee
authors.forename: Ann
authors.initials: A
authors.lastname: Romine
authors.forename: Eric
authors.initials: E
authors.lastname: Brown
authors.forename: Paul
authors.initials: P
authors.lastname: Thuras
authors.forename: Susanne
authors.initials: S
authors.lastname: Lee
authors.forename: S Charles
authors.initials: SC
authors.lastname: Schulz
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001066:Appetite / Q000187:drug effects; D001143:Arousal / Q000187:drug effects; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010054:Brief Psychiatric Rating Scale; D003987:Dibenzothiazepines / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010552:Personality Assessment; D000069348:Quetiapine Fumarate
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate